GSK 2838497A

Drug Profile

GSK 2838497A

Alternative Names: GSK 2231395A; GSK 2254232A; GSK 2254233A; GSK 2838500A; GSK 2838501A; GSK 2838502A; GSK 2838503A; GSK 2838504A; GSK 2838505A; GSK 2838506A; GSK 2838507A; GSK 2838508A; GSK2838497A; Non-typeable Haemophilus influenzae (NTHi) vaccine - GlaxoSmithKline; Non-typeable Haemophilus influenzae/pneumococcal adult vaccine - GlaxoSmithKline; NTHi-10-AS01E; NTHi-Pneumo

Latest Information Update: 15 May 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Haemophilus vaccines; Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Haemophilus infections
  • No development reported Pneumococcal infections

Most Recent Events

  • 19 Apr 2017 GlaxoSmithKline completes the phase II NTHI 004 trial for Haemophilus infections (Prevention, In adults and the elderly with COPD) in United Kingdom and Sweden (NCT02075541)
  • 01 Jul 2014 Phase-II clinical trials in Haemophilus infections (Prevention, In adults and the elderly with COPD) in United Kingdom (IM)
  • 01 Jan 2014 GlaxoSmithKline completes a phase I trial in Haemophilus infections (in volunteers, prevention) in Belgium (NCT01678677)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top